Nutra Pharma raises $9.6M in stock financing deal

Nutra Pharma has struck a deal to sell 24 million shares of its stock to SBI Brightline for $9.6 million. Additional warrants will be issued that will net the company another $2.4 million. Boynton Beach, Florida-based Nutra Pharma has been developing drugs for MS and HIV. "This financing provides us with the capital to meet our near-term budgets and the financial leverage to allow us to become revenue generating and fund the clinical trials of our biotech investments," commented Rik J. Deitsch, CEO of Nutra Pharma.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.